Trial Profile
A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aciclovir/hydrocortisone (Primary) ; Aciclovir
- Indications Herpes labialis
- Focus Registrational; Therapeutic Use
- Sponsors Medivir AB
- 08 Dec 2010 Results presented at the 45th American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition, according to a Medivir media release.
- 01 Oct 2008 Medivir submitted NDA to the US FDA, according to media release.
- 08 Sep 2008 New trial record.